Niloy A. Singh

Reconstruction of septin higher-order nano-size structures in ovarian cancer cells uncover susceptibility to the septin-targeting small molecule UR214-9

This paper demonstrates that UR214-9 disrupts septin hetero-octamerization, leading to aberrant structures and impairing cancer cell functions.

IL1β/IL1R1/IRAK4 Drives Inflammatory Ovarian Cancer Seeding at the inflamed sites and Is Reversed by an IRAK4 inhibitor UR241-2

This paper identifies the IL1β/IL1R1/IRAK4 axis as critical for inflammation-driven ovarian cancer metastasis and shows that IRAK4 inhibition with UR241-2 reduces tumor seeding and activates antitumor immune responses.

Effects of a novel proteasome inhibitor, UR238 on the tumor immune microenvironment and growth in epithelial ovarian cancer

PSP-0119: Targeted IRAK4 Degradation as a Novel Therapeutic Strategy for FLT3-Mutant AML

This study identifies PSP-0119, an IRAK4 degrader, as a promising therapy for FLT3-mutant AML by inhibiting IRAK4 activity and showing antileukemic effects in cell lines and xenograft models.

IL-1β/IRAK4 Axis Promotes Ovarian Tumor Development at the Mesothelium Injury Sites

This paper develops a MIM model to study EOC metastasis at mesothelial injury sites and shows IRAK4 inhibitors reduce tumor burden more effectively than IL-1/IL-1R1 targeting agents.